LIGAND PHARMACEUTICALS INCORPORATED Current Foreign Tax Expense (Benefit)
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) reported Current Foreign Tax Expense (Benefit) of $3.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentForeignTaxExpenseBenefit · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED current foreign tax expense (benefit) for fiscal 2025 was $3.61M, a 7.66% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED current foreign tax expense (benefit) for fiscal 2024 was $3.35M, a 330.13% increase from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED current foreign tax expense (benefit) for fiscal 2023 was $780.00K, a 72.57% increase from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED current foreign tax expense (benefit) for fiscal 2022 was $452.00K.
| Period end | Current Foreign Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $3.61M 10-K · filed 2026-02-27 |
| 2024-12-31 | $3.35M 10-K · filed 2026-02-27 |
| 2023-12-31 | $780.00K 10-K · filed 2026-02-27 |
| 2022-12-31 | $452.00K 10-K · filed 2025-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2020-12-31 | $23.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | -$66.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | -$158.00K 10-K · filed 2021-02-24 |
| 2017-12-31 | $261.00K 10-K · filed 2020-02-27 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 |